新月直播app下载

The T-cell engager field is advancing faster than ever. With multiple clinical approvals validating the staying power of this modality, and anew wave of next-generation solid tumorandautoimmune programsmoving rapidly towards the clinic, the momentum behind T-Cell engagers has never been stronger. These therapies are increasingly cited as one of the most promising drivers of the next era of immunotherapy.

Over the past year, the sector has experienced a surge of investment, deal-making and strategic collaboration. Landmark partnerships such asBMSxJanuX Therapeutics,Candid TherapeuticsxWuXi BiologicsandAbbViexEvolveImmunesignal growing confidence in the transformative potential of immune-redirecting platforms and reinforce commitment to advancing TCE innovation across oncology and autoimmune disease.

Moving from Boston to San Diego for 2026, the8thT-Cell Engager Therapeutics Summitstands as the industry's most comprehensive end-to-end meeting dedicated to advancing, optimizing and translating T-cell engagers.

This case-study driven forum is designed to equip engineering, discovery, RandD, translational and clinical development teams with theactionable insights needed to engineer safer,more potent,durable and precisely targets TCEs for solid tumors, while also spotlighting the breakthroughs extending engager biology into autoimmune and inflammatory diseases.

If accelerating your TCE pipeline is a priority, this is a meeting you cannot afford to miss.